Goldman Sachs’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.93M | Buy |
743,124
+154,424
| +26% | +$1.39M | ﹤0.01% | 3377 |
|
|
2025
Q4 | $5.27M | Sell |
588,700
-173,077
| -23% | -$1.64M | ﹤0.01% | 3690 |
|
|
2025
Q3 | $7.24M | Buy |
761,777
+386,985
| +103% | +$3.88M | ﹤0.01% | 3294 |
|
|
2025
Q2 | $3.3M | Buy |
374,792
+179,979
| +92% | +$1.46M | ﹤0.01% | 3800 |
|
|
2025
Q1 | $1.46M | Sell |
194,813
-55,122
| -22% | -$438K | ﹤0.01% | 4398 |
|
|
2024
Q4 | $2.08M | Buy |
249,935
+124,100
| +99% | +$1.06M | ﹤0.01% | 4242 |
|
|
2024
Q3 | $873K | Buy |
125,835
+91,355
| +265% | +$620K | ﹤0.01% | 4730 |
|
|
2024
Q2 | $169K | Buy |
34,480
+14,455
| +72% | +$68.5K | ﹤0.01% | 5307 |
|
|
2024
Q1 | $116K | Sell |
20,025
-15,678
| -44% | -$96.4K | ﹤0.01% | 5220 |
|
|
2023
Q4 | $234K | Buy |
35,703
+5,337
| +18% | +$25K | ﹤0.01% | 5097 |
|
|
2023
Q3 | $146K | Sell |
30,366
-6,257
| -17% | -$31.2K | ﹤0.01% | 5113 |
|
|
2023
Q2 | $187K | Buy |
36,623
+3,792
| +12% | +$20.4K | ﹤0.01% | 5204 |
|
|
2023
Q1 | $181K | Buy |
32,831
+9,507
| +41% | +$50.3K | ﹤0.01% | 5332 |
|
|
2022
Q4 | $107K | Sell |
23,324
-3,089
| -12% | -$15.7K | ﹤0.01% | 5467 |
|
|
2022
Q3 | $165K | Sell |
26,413
-50,727
| -66% | -$287K | ﹤0.01% | 5545 |
|
|
2022
Q2 | $344K | Sell |
77,140
-75,018
| -49% | -$342K | ﹤0.01% | 5333 |
|
|
2022
Q1 | $766K | Sell |
152,158
-38,632
| -20% | -$246K | ﹤0.01% | 5040 |
|
|
2021
Q4 | $1.66M | Buy |
190,790
+22,101
| +13% | +$197K | ﹤0.01% | 4409 |
|
|
2021
Q3 | $1.57M | Buy |
+168,689
| New | +$1.7M | ﹤0.01% | 4393 |
|
|
2021
Q2 | – | Sell |
-33,907
| Closed | -$312K | – | 6567 |
|
|
2021
Q1 | $312K | Buy |
+33,907
| New | +$296K | ﹤0.01% | 5408 |
|
|
2020
Q2 | – | Sell |
-2,410
| Closed | -$9K | – | 5523 |
|
|
2020
Q1 | $9K | Buy |
2,410
+3
| +0.1% | +$17 | ﹤0.01% | 5169 |
|
|
2019
Q4 | $15K | Sell |
2,407
-100
| -4% | -$794 | ﹤0.01% | 5176 |
|
|
2019
Q3 | $28K | Buy |
+2,507
| New | +$45.3K | ﹤0.01% | 5089 |
|
|
2018
Q3 | – | Sell |
-1,414
| Closed | -$147K | – | 5821 |
|
|
2018
Q2 | $147K | Buy |
+1,414
| New | +$138K | ﹤0.01% | 5098 |
|
|
2017
Q3 | – | Sell |
-1,111
| Closed | -$71K | – | 6894 |
|
|
2017
Q2 | $71K | Sell |
1,111
-123
| -10% | -$8.1K | ﹤0.01% | 6260 |
|
|
2017
Q1 | $97K | Sell |
1,234
-59
| -5% | -$3.58K | ﹤0.01% | 6075 |
|
|
2016
Q4 | $61K | Buy |
1,293
+70
| +6% | +$4.3K | ﹤0.01% | 6335 |
|
|
2016
Q3 | $88K | Buy |
1,223
+240
| +24% | +$17.1K | ﹤0.01% | 6287 |
|
|
2016
Q2 | $63K | Sell |
983
-4,377
| -82% | -$720K | ﹤0.01% | 6335 |
|
|
2016
Q1 | $1.24M | Buy |
5,360
+1,453
| +37% | +$352K | ﹤0.01% | 3899 |
|
|
2015
Q4 | $1.24M | Buy |
+3,907
| New | +$1.06M | ﹤0.01% | 4084 |
|
Other funds holding ZVRA
WP
NCM
VCM
ACM
Goldman Sachs's ZVRA Position: Q1 2026 in Review
Goldman Sachs increased its Zevra Therapeutics (ZVRA) stake by 26% in Q1 2026, buying an estimated $1.39M and bringing the position to 743,124 shares worth $6.93M. The position accounts for ﹤0.01% of the portfolio, ranked #3377.
Goldman Sachs first reported a position in ZVRA in Q4 2015 and has held it in 31 quarters since. The position peaked at $7.24M in Q3 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.
- Goldman Sachs held 743,124 shares of Zevra Therapeutics worth $6.93M as of Q1 2026.
- Goldman Sachs bought 154,424 Zevra Therapeutics shares in Q1 2026, an estimated $1.39M.
- Zevra Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3377 holding.
- Goldman Sachs first reported a position in Zevra Therapeutics in Q4 2015 and has held it in 31 quarters since.
- Goldman Sachs's Zevra Therapeutics position peaked at $7.24M in Q3 2025.
- 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.